Latest Conference

As part of ongoing coverage of DCAT, the PharmTech editors touched base with Pierre Luzeau, CEO of Seqens. In in our discussion, Pierre discussed various aspects of sustainability, including:

The extensive measures his company has put in place to committ to sustainability

Underappreciated practices and techniques that contribute to sustainability

Why sustainability will be so pivotal for biopharma companies over the course of the next ten years.

For more of our coverage on DCAT in 2023, viewers can visit 

Articles

Pierre Luzeau, CEO of Seqens, discusses Seqen's commitment to sustainability and how one can work toward it within their own company.

Setting Sustainability Goals with Pierre Luzeau (DCAT 2023)

As part of ongoing coverage of DCAT, the PharmTech editors touched base with Anil Kane, executive director, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific. In in our discussion, Anil discussed various topics within the outsourcing market, including:

The increased interest in technologies like cell and gene therapies and oral biologics

The continued rise of the "end-to-end" CDMO model and why biopharma partners are seeking it out

Recent investments made in new spaces by Thermo Fisher Scientific

Anil Kane, executive director, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, discusses the growing role of CDMOs in the biopharma industry

Discussing the Growing Role of CDMOs with Anil Kane (DCAT 2023)

As part of ongoing coverage of DCAT, the PharmTech editors touched base with Stephen Houldsworth, vice-president and head of Platform Management & Marketing at CordenPharma. In in our discussion, Stephen touched on various topics within the outsourcing market, including:

Recent investments and the strategic rationale behind them.

Ongoing industry trends and what customers are looking for.

Bold predictions for where the industry will be five years down the line.

Stephen Houldsworth, VP and Head of Platform Management & Marketing at CordenPharma, dives into ongoing trends in the outsourcing space.

Illuminating the State of Outsourcing with Stephen Houldsworth (DCAT 2023)

 editors were in attendance at DCAT Week 2023 from March 20 - March 25! Bookmark this page for highlights from various interviews conducted throughout the week.

Discussing the Growing Role of CDMOs with Anil Kane

Anil Kane, executive director, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, discusses the growing role of CDMOs in the biopharma industry.

Setting Sustainability Goals with Pierre Luzeau

Highlights from DCAT Week 2023, hosted from March 20 - March 25.

DCAT 2023 Highlights

What sets Logan’s equipment apart from other manufacturers

Videos

Logan Instruments discuses diffusion cell testing and what sets their company apart from other manufacturers.

Interview with Logan Instruments (AAPS 2022)

Overcoming formulation challenges in converting liquids into solid dose,

Turning soft gel into tablets, enhancing dissolution,

Simplifying modified-release formulations

Anthony Carpanzano, Director of R&D at JRS Pharma, discussed ongoing formulation challenges and trends.

Interview with Anthony Carpanzano (AAPS 2022)

Podcasts

Allison Labriola, Senior Technical Sales Representative, at JRS Pharma is interviewed by the Editorial Director of Pharmaceutical Technology Chris Spivey  about how the food industry is affecting the pharmaceutical industry. 

How Changing Regulations Impact Pharmaceutical Film Coating Formulations (AAPS 2022)

This video is an interview with Jon Brice, Vice President of Business Development at Asymchem at the AAPS Conference in Boston, Massachusetts.

 Asymchem Interview (AAPS 2022)

 interviewed Vibha Jawa, executive director at Bristol Myers Squibb, and Luke Schenck, principal scientist at Merck & Co. We spoke with Vibha Jawa about her expertise in the field of cell & gene therapies, specifically CAR-T cells. Luke Schenck discussed his knowledge on co-processed APIs. To see the highlights of our interviews with these experts, click the video below.

Vibha Jawa, executive director at Bristol Myers Squibb, and Luke Schenck, principal scientist at Merck & Com, discuss cell & gene therapies and co-processed APIs respectively.

Latest Conference Articles